Acromegaly is a rare and chronic disorder characterized by excess growth hormone secretion and elevated insulin-like growth factor-1 levels, most often caused by a pituitary Adenoma.
Epidemiology Insights
- The total Acromegaly prevalent cases in 2017 was 64,508
- The diagnosed Acromegaly patient pool cases in 2017 was 49,814
- The prevalent population of Acromegaly in the United States in 2017 was 28,671
- The prevalent cases of Acromegaly in Japan in 2017 was 10,690
- EU5 countries occupied around 38.98% of the patient pool amongst 7MM in 2017
Acromegaly Market Drivers
- Robust pipeline
- Increase in Prevalence
- More efficacious mono and combination therapies
Acromegaly Market Barriers
- Economic burden
- Low disease awareness and delay in diagnosis
- No standard cure available
1. Key Insights
2. Executive Summary of Acromegaly
3. Competitive Intelligence Analysis for Acromegaly
4. Acromegaly: Market Overview at a Glance
4.1. Acromegaly Total Market Share (%) Distribution in 2017
4.2. Acromegaly Total Market Share (%) Distribution in 2030
5. Acromegaly: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Acromegaly Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Acromegaly Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Acromegaly Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Acromegaly Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Acromegaly Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Acromegaly Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Acromegaly Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Acromegaly Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Acromegaly Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Acromegaly Treatment and Management
8.2. Acromegaly Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Acromegaly Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Acromegaly: Seven Major Market Analysis
13.1. Key Findings
13.2. Acromegaly Market Size in 7MM
13.3. Acromegaly Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Acromegaly Total Market Size in the United States
15.1.2. Acromegaly Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Acromegaly Total Market Size in Germany
15.3.2. Acromegaly Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Acromegaly Total Market Size in France
15.4.2. Acromegaly Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Acromegaly Total Market Size in Italy
15.5.2. Acromegaly Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Acromegaly Total Market Size in Spain
15.6.2. Acromegaly Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Acromegaly Total Market Size in the United Kingdom
15.7.2. Acromegaly Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Acromegaly Total Market Size in Japan
15.8.3. Acromegaly Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Acromegaly
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/